Archive | Uncategorized RSS feed for this section

Hot Investor Mandate 20: Southeast Family Office Looks US-Wide for Medtech Deals

21 Sep

A family office based in the southeast USA focuses its investment interests in healthcare, real estate, energy, and IT. The firm makes equity investments ranging from early-stage to full on commercialization, but also provides debt and convertible loan financing. The firm generally looks for USA-based opportunities but may consider deals outside of the USA and has a track record of working with companies globally. The firm seeks to make approximately 6-10 investments per year.

In the life sciences, the firm has a strong interest in medical device and diagnostic companies. The firm considers healthcare IT opportunities to a lesser degree, and will not consider biopharma companies for the most part. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. The firm is very opportunistic regarding the company’s stage of development and will consider products that are both on- and off-market.

The firm is looking for privately held companies backed by an experienced management team. Companies should have a strong exit strategy, including having a direct line of contact with strategic or financial buyers. The firm is open to both leading and co-investing in a financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 2: Cross-Border VC Interested in Early Stage Life Science, Focused on CNS Drugs

27 Jul

A healthcare-focused venture capital firm based in Taiwan is investing from its new fund that is set to close in Q3 2017. The firm seeks to lead or co-invest in Pre-A to Series A rounds. Typical allocation size ranges from US$500 K to 1 million. The firm is looking for companies across the world with a focus on North America and Europe.

The firm is most interested in therapeutic projects, especially in the CNS space. The firm prefers assets with preclinical or early clinical validation. The firm is open to all modalities. The firm also considers medical devices and diagnostic technologies.

The firm is looking for experienced teams and typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Early Bird Rate Extended

21 Oct


We are currently experiencing technical issues regarding RESI Registration due to the wide spread internet outages. We will be extending the RESI Earlybird Rate through Monday, 10/24 at 5pm ET. We apologize for any inconvenience!

If you have any questions, please call (617) 580-5013 or email

LSN Summer Reading Series Chapter 6: “Branding and Messaging”

2 Jul

By Michael Quigley, Director of Research, LSN

mike-2Last week we discussed how to determine where your company fits within your marketplace. Once you have completed that process, the next step in a fundraising campaign is to develop your marketing materials. In this week’s edition of the summer reading series, we describe the importance of and what constitutes a strong set of marketing materials in the life science fundraising world. While your team and your technology are what will ultimately secure an allocation, having marketing collateral that clearly and concisely communicates your message will help you tremendously in getting in the door with investors.

Chapter 6 of The Life Science Executive’s Fundraising Manifesto discusses in depth the different pieces of marketing collateral you should be putting into the marketplace and how to develop everything from your logo to your pitch deck.

Click here to download/print the PDF.

Join us next week for Chapter 7: “Building a Web Presence,” where we take an even deeper dive into how best to use a website as a fundraising tool.

Enjoyed the preview? Buy now from or Barnes & Noble


Hot Life Science Investor Mandate 4: VC Fund out of Southern United States Looking for Personalized Medicine Diagnostics

2 Jul

A venture capital firm based in the southern United States is currently making investments out of its vintage 2013. The fund currently has approximately $200 under management. The firm is looking to make equity investments in companies ranging from $500,000 to $3million. The firm will invest in companies across the United States and plans to make approximately 3-4 investments over the next 6-9 months.

The firm is currently most interested in areas of personalized medicine diagnostics, particularly in the genomic and proteomic subsectors. Other areas of high interest include: digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit. The firm is looking to invest in early to mid-stage companies and generally does not make seed investments.

The firm invests in privately help companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 1: US Based Hedge Fund Seeking Range of Therapeutics Opportunities Globally

7 May

A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Life Science Investor Mandate 2: Family Office Seeking 510k Devices in Eastern US

7 May

The operational and investment arm of a family office is looking to make equity investments into early stage companies and small mid-market growth companies ranging from $.5 to $1 million. The firm is very open to syndication particular with early stage deals and is capable of providing additional capital in follow on rounds when appropriate. The firm prefers to invest in companies located in the eastern United States and looks to make approximately 1-2 new investments per year.

The firm is looking for companies in the Medical Technology and Diagnostics space. Within these areas the firm is looking for 510k devices that are more technically based with a particular interest in hospital equipment and professional diagnostics. The firm is not interest in devices where the final consumer is the patient. The firm is looking to devices that improve the standard of care and is willing to invest in companies at all phases of development. The firm is generally open to all indications.

If you are interested in more information about this investor and other investors tracked by LSN, please email